Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

NCT00367016 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Asthma
Allergic Rhinitis
Atopic Dermatitis

Interventions

DRUG: Omalizumab
DRUG: Placebo

Sponsor

University of California, Davis